The Philadelphia Inquirer
By Rob Waters, Bloomberg News
Unsealed documents in a whistle-blower lawsuit allege that drugmaker Janssen Pharmaceutica, of Titusville, N.J., misled Texas officials about an antipsychotic drug to increase prescriptions.
The lawsuit claims that Janssen, a subsidiary of Johnson & Johnson, of New Brunswick, N.J., caused Texas to overspend last year on Risperdal, a top-selling schizophrenia drug.
The case, one of several against makers of antipsychotics in several states, centers on Texas prescription guidelines that require doctors to give priority to newer, more expensive drugs in state-funded treatment of mental-health patients.
The Texas guidelines have been adopted by several other states, including Pennsylvania. The complaint was initiated in 2004 by Allen Jones, a former investigator for Pennsylvania’s Office of the Inspector General. Jones was fired after questioning the Pennsylvania system and divulging information about his investigation without permission…